A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Summary

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.

Timeline

Start

2022-04-01

Primary completion

2025-02-21

Completion

2027-06

Outcome

Met primary endpoint

release “VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints.” takeda.com ↗

Drugs

Indications